» Articles » PMID: 38273292

Intratumoral Microorganisms in Tumors of the Digestive System

Overview
Publisher Biomed Central
Date 2024 Jan 25
PMID 38273292
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors of the digestive system pose a significant threat to human health and longevity. These tumors are associated with high morbidity and mortality rates, leading to a heavy economic burden on healthcare systems. Several intratumoral microorganisms are present in digestive system tumors, and their sources and abundance display significant heterogeneity depending on the specific tumor subtype. These microbes have a complex and precise function in the neoplasm. They can facilitate tumor growth through various mechanisms, such as inducing DNA damage, influencing the antitumor immune response, and promoting the degradation of chemotherapy drugs. Therefore, these microorganisms can be targeted to inhibit tumor progression for improving overall patient prognosis. This review focuses on the current research progress on microorganisms present in the digestive system tumors and how they influence the initiation, progression, and prognosis of tumors. Furthermore, the primary sources and constituents of tumor microbiome are delineated. Finally, we summarize the application potential of intratumoral microbes in the diagnosis, treatment, and prognosis prediction of digestive system tumors. Video Abstract.

Citing Articles

From colon wall to tumor niche: Unraveling the microbiome's role in colorectal cancer progression.

Garcia Menendez G, Sichel L, Lopez M, Hernandez Y, Arteaga E, Rodriguez M PLoS One. 2024; 19(10):e0311233.

PMID: 39436937 PMC: 11495602. DOI: 10.1371/journal.pone.0311233.


Intratumoral Microbiota: Metabolic Influences and Biomarker Potential in Gastrointestinal Cancer.

Bi X, Wang J, Liu C Biomolecules. 2024; 14(8).

PMID: 39199305 PMC: 11353126. DOI: 10.3390/biom14080917.

References
1.
Kanwal F, Singal A . Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019; 157(1):54-64. PMC: 6636644. DOI: 10.1053/j.gastro.2019.02.049. View

2.
Zhang S, Zhang S, Ma X, Zhan J, Pan C, Zhang H . Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients. Front Cell Infect Microbiol. 2023; 13:1165790. PMC: 10174428. DOI: 10.3389/fcimb.2023.1165790. View

3.
Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

4.
Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E . Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(21):8668-73. PMC: 3666740. DOI: 10.1073/pnas.1211287110. View

5.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View